Risk of Non-AIDS-Related Mortality May Exceed Risk of AIDS-Related Mortality Among Individuals Enrolling Into Care With CD4+ Counts Greater Than 200 Cells/mm3
暂无分享,去创建一个
[1] Kholoud Porter,et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion , 2006, AIDS.
[2] P. Morlat,et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. , 2004, International journal of epidemiology.
[3] A. Mocroft,et al. Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy , 2004, AIDS.
[4] D. Vlahov,et al. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. , 2004, The Journal of infectious diseases.
[5] M. Zwahlen,et al. All cause mortality in the Swiss HIV cohort study from 1990 to 2001 in comparison with the Swiss population , 2004, AIDS.
[6] Mark A van de Wiel,et al. Mortality and progression to AIDS after starting highly active antiretroviral therapy , 2003, AIDS.
[7] D. Vlahov,et al. Longitudinal patterns of drug injection behavior in the ALIVE Study cohort,1988-2000: description and determinants. , 2003, American journal of epidemiology.
[8] J. Sterne,et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies , 2003, The Lancet.
[9] A. Mocroft,et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study , 2003, The Lancet.
[10] A. Mocroft,et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study , 2002, AIDS.
[11] Mary Young,et al. Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. , 2002, The American journal of medicine.
[12] Jonathan AC Sterne,et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.
[13] R. Byers,et al. Trends in Diseases Reported on U.S. Death Certificates That Mentioned HIV Infection, 1987‐1999 , 2002, Journal of acquired immune deficiency syndromes.
[14] R. Byers,et al. Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999. , 2002 .
[15] M. Lederman,et al. Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995--1999. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] Anne M Johnson,et al. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. , 1999, Journal of acquired immune deficiency syndromes.
[17] R. Chaisson,et al. Natural history of HIV infection in the era of combination antiretroviral therapy. , 1999, AIDS.
[18] J. Ward,et al. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group. , 1999, AIDS.
[19] D. Revicki,et al. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter , 1999 .
[20] A Muñoz,et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. , 1998, JAMA.
[21] D. Revicki,et al. A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease , 1998, AIDS.
[22] P. Kissinger,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.
[23] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[24] Manuel Battegay,et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study , 1997, BMJ.
[25] M Lunn,et al. Applying Cox regression to competing risks. , 1995, Biometrics.
[26] Jeffrey J. Gaynor,et al. On the Use of Cause-Specific Failure and Conditional Failure Probabilities: Examples from Clinical Oncology Data , 1993 .
[27] D. Cox,et al. THE ANALYSIS OF EXPONENTIALLY DISTRIBUTED LIFE-TIMES WITH Two TYPES OF FAILURE , 1959 .
[28] R. Moore,et al. Understanding the clinical and economic outcomes of HIV therapy: the Johns Hopkins HIV clinical practice cohort. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[29] B. Efron. The jackknife, the bootstrap, and other resampling plans , 1987 .